



*Keenan*<sup>®</sup>

Keenan Pharmacy Services  
San Joaquin Valley Insurance Authority  
(SJVIA)  
Consultants Report: Q4 2024

# SJVIA- EmpiRx Health – Q2 and Q3 2024 Highlights

- SJVIA's total plan cost increased in Q4-2024 by 22% to \$8,004,963 (Q4-2023 \$6,527,725)
  - Tulare: \$3,468,351 in Plan Cost
  - Fresno: \$4,536,613 in Plan Cost
  - The increase in plan spend can be attributed to an increase in Rx count.
- Specialty claims plan cost increased slightly in Q4-2024
  - Q4-2023 \$2,507,686 (Q4-2023 - \$2,495,776)
  - 633 Scripts filled in Q4-2024 (Q4-2023 – 664)
    - Tulare: 266
    - Fresno: \$407
- Patient Saver Plus Program Savings (*formerly known as Variable Copay Assistance (VCAP) aka bWell*)
  - SJVIA Total Savings May – December: \$330,831
    - Tulare: \$166,763
    - Fresno: \$164,068
- Rebates:
  - Q1-2024 net rebate amount is \$1,618,600 (includes \$382,745 true up payment in August)
  - Q2 -2024 net rebate amount is \$1,730,100
  - Q3 – 2024 net rebate amount is \$1,766,350
  - Q4 – 2024 net rebate amount is \$1,648,300
- Clinical Savings: January – December 2024: \$6,939,480 (original estimate number was \$1,100,000)
  - SJVIA Tulare: Jan-Dec 2024, **\$2,730,999**
  - SJVIA Fresno: Jan-Jun 2024, **\$4,208,481**

## KPS Audit

KPS conducts a yearly financial audit of EmpiRx clinical savings, Average Wholesale Price (AWP) discounts and rebate performance against the client's aggregate contractual guarantees. 2024 Audit is expected to be completed by 5/30/25



# Top Clinical Cost Drivers by Drug Q1 – Q3 2024

| Top Drugs by Ingredient Cost              |   |                         |                |                      |             |           |                 |
|---|---|-------------------------|----------------|----------------------|-------------|-----------|-----------------|
| Based on Paid Date: 01/01/2024-12/31/2024 |   |                         |                |                      |             |           |                 |
| Drug Label Name                           | Drug Group                                    | Brand Generic Indicator | Formulary Tier | Speciality Indicator | Claim Count | Utilizers | Ingredient Cost |
| WEGOVY                                    | ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS | B                       | 3              | N                    | 1,713       | 364       | \$2,539,310.43  |
| MOUNJARO                                  | ANTIDIABETICS                                 | B                       | 2              | N                    | 1,254       | 223       | \$1,583,939.05  |
| OZEMPIC                                   | ANTIDIABETICS                                 | B                       | 2              | N                    | 1,057       | 327       | \$1,440,156.48  |
| DUPIXENT                                  | DERMATOLOGICALS                               | B                       | 2              | Y                    | 246         | 42        | \$958,800.58    |
| JARDIANCE                                 | ANTIDIABETICS                                 | B                       | 2              | N                    | 562         | 169       | \$783,515.21    |
| OZEMPIC (2 MG/DOSE)                       | ANTIDIABETICS                                 | B                       | 2              | N                    | 514         | 157       | \$705,691.82    |
| ZEPBOUND                                  | ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS | B                       | 3              | N                    | 558         | 147       | \$645,540.27    |
| HUMIRA PEN                                | ANALGESICS - ANTI-INFLAMMATORY                | B                       | 2              | Y                    | 71          | 22        | \$569,205.60    |
| OZEMPIC (1 MG/DOSE)                       | ANTIDIABETICS                                 | B                       | 2              | N                    | 391         | 159       | \$544,276.36    |
| EMPAVELI                                  | HEMATOLOGICAL AGENTS - MISC.                  | B                       | 2              | Y                    | 13          | 1         | \$509,733.51    |
| STELARA                                   | DERMATOLOGICALS                               | B                       | 2              | Y                    | 17          | 6         | \$457,903.54    |
| TREMFYA                                   | DERMATOLOGICALS                               | B                       | 2              | Y                    | 33          | 10        | \$440,211.79    |
| TRULICITY                                 | ANTIDIABETICS                                 | B                       | 2              | N                    | 306         | 82        | \$413,004.23    |
| RYBELSUS                                  | ANTIDIABETICS                                 | B                       | 2              | N                    | 232         | 70        | \$411,397.53    |
| OZEMPIC (0.25 OR 0.5 MG/DOSE)             | ANTIDIABETICS                                 | B                       | 2              | N                    | 354         | 158       | \$405,045.54    |
| HUMIRA (2 PEN)                            | ANALGESICS - ANTI-INFLAMMATORY                | B                       | 2              | Y                    | 55          | 18        | \$404,807.03    |
| FARXIGA                                   | ANTIDIABETICS                                 | B                       | 2              | N                    | 271         | 106       | \$400,926.26    |
| SKYRIZI PEN                               | DERMATOLOGICALS                               | B                       | 2              | Y                    | 19          | 8         | \$394,201.61    |
| RINVOQ                                    | ANALGESICS - ANTI-INFLAMMATORY                | B                       | 2              | Y                    | 55          | 10        | \$371,675.64    |
| ELIQUIS                                   | ANTICOAGULANTS                                | B                       | 2              | N                    | 315         | 82        | \$338,629.68    |
| JANUVIA                                   | ANTIDIABETICS                                 | B                       | 2              | N                    | 250         | 77        | \$336,202.00    |
| BIKTARVY                                  | ANTIVIRALS                                    | B                       | 2              | Y                    | 83          | 11        | \$329,806.51    |
| TRIKAFTA                                  | RESPIRATORY AGENTS - MISC.                    | B                       | 2              | Y                    | 11          | 1         | \$304,854.22    |
| PAXLOVID (300/100)                        | ANTIVIRALS                                    | B                       | 2              | N                    | 200         | 224       | \$298,306.98    |
| KORLYM                                    | ANTIDIABETICS                                 | B                       | 3              | Y                    | 7           | 1         | \$288,953.54    |



# New Medications Available in the Market

- **New Biosimilar's in 2025**

- **Avtozma (tocilizumab-anoh):**

- Approved in January 2025, this biosimilar to Actemra (tocilizumab) is indicated for rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, and systemic JIA.

- **Merilog (insulin aspart-szjj):**

- Approved in February 2025, this is the first biosimilar to NovoLog (insulin aspart). It is a rapid-acting insulin product for the treatment of type 1 and type 2 diabetes.

- **Ospomyvtm and Xbryktm (denosumab-dssb):**

- These biosimilars to Prolia and Xgeva (denosumab) were approved in February 2025. They are used for treating osteoporosis, bone metastases, and other bone-related conditions.

- **Omlyclo (omalizumab-igec)**

- Approved in March, the first and only biosimilar designated as interchangeable with Xolair (omalizumab) for the treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), Immunoglobulin E (IgE)-mediated food allergy, and chronic spontaneous urticaria (CSU)

- EmpiRx will be reviewing Formulary placement of these biosimilar's once they become available.

